Announcement on Obtaining Government Subsidies
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference: View Attachment
Announcement on Obtaining Government Subsidies
Filed with SSE ·
6ix hasn’t read this filing yet.
Shouyao Holdings Beijing Co. Ltd. on 6ix
Earlier from Shouyao Holdings Beijing
- Report for Q3 2025
- Announcement on Voluntary Disclosure of Acceptance of the New Drug Application for Marketing of the RET Inhibitor Sotolitinib Tablets (SY-5007)
- Announcement on Completing Industrial and Commercial Change Registration and Filing, as well as Obtaining Renewed "Business License"
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
- Semi-annual Evaluation Report on "Corporate Value and Return Enhancement" Action Plan 2025
Later from Shouyao Holdings Beijing
- Preliminary Earnings Estimate for 2025
- Announcement on Voluntary Disclosure of MAT2A Inhibitor SY-9453 Obtaining the Notice of Approval for Drug Clinical Trials
- Announcement on Retirement and Resignation of Core Technical Personnel
- Announcement on Resignation of Director
- Announcement on the Adjustment of the Collaborative R&D Model for JAK2 Inhibitor Antitumor New Drugs
Follow Shouyao Holdings Beijing into a list and get an email when it puts out news.
Follow Shouyao Holdings Beijing